Mental disorders have an immense toll on the healthcare system and society at large. More than 3.5 hundred million people live with depression and 3.7 hundred million people suffer from, anxiety disorders globally. In this systematic review, the authors examine clinical trials from 1960 onward that evaluate various psychedelics as monotherapy or adjunct therapy for mood disorders and other mental disorders. Included studies assessed four psychedelics for treatment of mood disorders. The review found an overall improvement in negative mood, with psilocybin showing the strongest effect. The authors also found that LSD was associated with improvement when treating alcohol use disorder, while MDMA-assisted psychotherapy was associated with reduced PTSD symptoms. The authors note these findings suggest psychedelic-assisted treatment may offer new opportunities, but many of the studies were a small sample size, leaving potential for adverse effects and abuse.
Contingency Management for Stimulant Use Disorder and Association With Mortality: A Cohort Study
Stimulant overdose deaths continue to rise, even as opioid overdoses decline—and there are still no FDA-approved...
0 Comments